Literature DB >> 18187966

The role of emollients in the management of diseases with chronic dry skin.

E Proksch1.   

Abstract

Dry skin is a common skin condition as well as a key aspect of a number of diseases such as atopic dermatitis and psoriasis but also of other diseases and systemic conditions. Dry skin has an impact on the patient in terms of discomfort, pruritus and impaired quality of life. Within the overall treatment regimen for these diseases, the use of emollients to manage dry skin plays a considerable role in managing skin conditions. In atopic dermatitis and psoriasis, emollients help to improve skin condition and to reduce pruritus alongside more potent pharmacological agents. It is important to choose an emollient that not only soothes and rehydrates the skin but also offers numerous other dermatological supporting roles, especially induction of proper epidermal differentiation. This review will explain the role of emollients within the management of diseases with dry skin as a major symptom and the components of an ideal emollient. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187966     DOI: 10.1159/000112957

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  10 in total

1.  [New insights into the pathogenesis of sensitive skin].

Authors:  E Proksch; S Weidinger
Journal:  Hautarzt       Date:  2011-12       Impact factor: 0.751

2.  Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial.

Authors:  Jens-Michael Jensen; Tanja Gau; Jürgen Schultze; Gunter Lemmnitz; Regina Fölster-Holst; Theodor May; Christoph Abels; Ehrhardt Proksch
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

Review 3.  [Epidermal barrier disorders in dermatoses].

Authors:  E Proksch; D Dähnhardt; R Fölster-Holst
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

4.  Formation and stability of oil-in-water nanoemulsions containing rice bran oil: in vitro and in vivo assessments.

Authors:  Daniela S Bernardi; Tatiana A Pereira; Naira R Maciel; Josiane Bortoloto; Gisely S Viera; Gustavo C Oliveira; Pedro A Rocha-Filho
Journal:  J Nanobiotechnology       Date:  2011-09-28       Impact factor: 10.435

5.  Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids.

Authors:  Hyun Jung Kim; Hyun Jung Park; Jae Nam Yun; Se Kyoo Jeong; Sung Ku Ahn; Seung Hun Lee
Journal:  Allergy Asthma Immunol Res       Date:  2011-02-14       Impact factor: 5.764

Review 6.  Moisturisers for the treatment of foot xerosis: a systematic review.

Authors:  Justin Parker; Rolf Scharfbillig; Sara Jones
Journal:  J Foot Ankle Res       Date:  2017-02-07       Impact factor: 2.303

7.  Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.

Authors:  Jiun-Wen Guo; Yu-Pin Cheng; Chih-Yi Liu; Haw-Yueh Thong; Chi-Jung Huang; Yang Lo; Chen-Yu Wu; Shiou-Hwa Jee
Journal:  Pharmaceutics       Date:  2020-05-17       Impact factor: 6.321

Review 8.  Thyroid hormone action in epidermal development and homeostasis and its implications in the pathophysiology of the skin.

Authors:  G Mancino; C Miro; E Di Cicco; M Dentice
Journal:  J Endocrinol Invest       Date:  2021-03-08       Impact factor: 4.256

9.  An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in Type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controlled trial.

Authors:  Adalberto Federici; Giovanni Federici; Massimo Milani
Journal:  BMC Dermatol       Date:  2012-09-25

10.  The effect of an emollient with benfothiamine and Biolin prebiotic on the improvement of epidermal skin function.

Authors:  Joanna Narbutt; Igor A Bednarski; Aleksandra Lesiak
Journal:  Postepy Dermatol Alergol       Date:  2016-06-17       Impact factor: 1.837

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.